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absTracT
Background and Aims: in this report, we present our experience with the transaortic 
transcatheter aortic valve implantation using the sapien valve. The procedural success, 
30-day outcome, and survival up to 2 years are compared with the transapical access 
performed in patients in our institution.
Material and Methods: of a total of 282 transcatheter aortic valve implantation patients, 
100 consecutive patients had a non-transfemoral approach. The transaortic and transapical 
access routes were used in 36 and 64 patients, respectively. The transaortic group had 
a higher mean logistic euroscore (32.6 vs 25.2, p = 0.021) and more patients with left 
ventricular ejection fraction less than 40% (33.3% vs 14.1%, p = 0.023).
Results: The respective technical success rates for the transaortic and transapical groups 
were 100% and 95.2% (p = ns). There were significantly more perioperative hemodynamic 
problems necessitating cardiopulmonary resuscitation or mechanical circulatory 
support in the transapical group (18.8% vs 2.8%, p = 0.023). The transaortic group had a 
slightly shorter hospital stay (7 vs 8 days, p = 0.018). The 30-day mortality was 8.6% and 
10.9% in the transaortic and transapical group, respectively (p = ns). combined safety 
outcome was similar in both groups at 30 days. The respective 1-year survival rates for 
the transaortic and transapical groups were 71.5% and 68.3%, respectively (p = ns).
Conclusion: The trans transcatheter aortic valve implantation is a considerable choice to 
transapical approach. despite a higher risk patient cohort, the clinical outcome is at least 
comparable to the transapical transcatheter aortic valve implantation, and it can be utilized as 
a second choice for patients with prohibitive iliac-femoral anatomy for transfemoral access.
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InTRODUCTIOn
Over the recent years, transcatheter aortic valve 
implantation (TAVI) has evolved from an experimen-
tal treatment modality to an essential part of clinical 
practice for patients with symptomatic severe aortic 
stenosis (AS) and who have either a high or prohibi-
tive risk for an open surgical aortic valve replacement 
(AVR) (1). In the majority of institutes, the transfemo-
ral (TF) is the preferred access route whenever it is fea-
sible. Even with this policy, an alternative access route 
is required in up to 30% of patients (2). Several differ-
ent options have been introduced, but for the SAPIEn 
valve, the transapical (TA) route is the original and 
most widely used alternative for the TF. However, the 
TA approach is reported to have a higher acute com-
plication rate and inferior survival than the TF (3–5). 
The novel transaortic (TAo) approach has recently 
been introduced as an alternative option for the TA (6, 
7). The TAo has potential theoretical advantages over 
the TA (6, 7), but up-to-date limited comparable data 
have been published on this matter (7, 8).
In this report, we present our experience with the 
TAo-TAVI using the SAPIEn valve. The procedural 
success, 30-day outcome, and survival up to 2 years 
are compared with our institutional TA patient cohort.
MATERIAL AnD METHODS
Between December 2008 and September 2014, 282 con-
secutive inoperable or high-risk patients with severe 
symptomatic AS were treated with the TAVI at the 
Helsinki University Hospital, Finland. These patients 
were prospectively included in our TAVI database. Of 
these, 100 patients who had a non-TF approach were 
included in this study. Adhering to the European 
Society of Cardiology (ESC)/European Association for 
Cardio-Thoracic Surgery (EACTS) treatment guide-
lines (9), the patients were considered for TAVI if they 
were deemed to be in high or prohibitive risk for the 
open surgical AVR. The EuroSCORE risk calculator 
was used as an aid in patient selection. The decision to 
proceed with TAVI was discussed by a dedicated heart 
team including experienced clinical and interventional 
cardiologists, cardiovascular surgeons, and cardiac 
anesthetists. All selected patients underwent complete 
clinical work-up that comprised physical examination, 
baseline laboratory testing, and evaluation of pulmo-
nary function and echo-Doppler study of the carotid 
arteries. The cardiac studies included a transthoracic 
echocardiography (TTE) and/or transesophageal 
echocardiography (TEE) and a coronary angiogram. 
For the technical feasibility of the TAVI, the gated 
multidetector computed tomography (MDCT) has 
become the primary imaging study to assess the anat-
omy of the aortic valve, aortic root, valve sizing, and 
vasculature with respect to the access options. Patients 
were selected to undergo the TAVI through the TF 
route whenever it was not prohibited by the size, calci-
fication, or tortuosity of the iliac-femoral arteries. From 
2008 to June 2011, the TA approach was utilized as the 
only alternative option to the TF-TAVI. Thereafter, the 
choice between the TAo and TA has been performed by 
the discretion of the heart team, being first utilized to 
the extreme-risk TAVI patients, such as those deemed 
to have a hostile apex (extreme friability, morbid obe-
sity, or high-dose immunosuppressive medication, 
etc.), poor left ventricular function, or severe chronic 
obstructive pulmonary disease (COPD). After the tech-
nical feasibility of the TAo-TAVI was established, it has 
been increasingly utilized as a second choice default 
option over the TA access.
The procedures were performed under general 
anesthesia using both fluoroscopic and TEE guidance 
using Edwards SAPIEn Transcatheter Heart Valve 
(Edwards Lifesciences, Irvine, CA). Over the course of 
time, all different generation SAPIEn valves (SAPIEn, 
XT, and S3) were used. The TAo-TAVI and TA-TAVI 
were performed as previously described (2, 7).
With respect to the TAo-TAVI, the access for all cases 
to the distal ascending aorta was gained via upper par-
tial sternotomy that was J-shaped to the right second 
or third intercostal space. Two pledgeted purse-string 
sutures were placed at the selected spot, which was 
chosen both by identifying a calcific-free spot in the 
preoperative MDCT and by directly palpating the 
aorta at a minimum distance of 5 cm from the aortic 
annulus. A direct needle puncture was performed to 
introduce a soft wire and a 6F multipurpose (MPA) 
catheter (Boston Scientific Inc., natick, MA). After the 
aortic valve was crossed with the wire, a pre-shaped 
ExtraStiff Amplatz guide wire (Boston Scientific Corp., 
natick, MA) was placed into the left ventricle followed 
by insertion of the Ascendra® sheath into the ascend-
ing aorta. First, a balloon valvuloplasty was performed 
with a 20 mm × 30 mm balloon followed by an Edwards 
SAPIEn valve deployment into the desired position. 
Both valvuloplasty and valve implantation were per-
formed during short bursts of rapid ventricular pacing 
at 160–180 beats/min.
The main study outcomes were Valve Academic 
Research Consortium (VARC)–defined procedural 
technical success, 30-day combined safety endpoint, 
and 12-month survival. According to VARC criteria, 
the technical success is defined as gaining successful 
vascular access, successful delivery and deployment 
of a single valve at the correct anatomical position, 
and appropriate prosthetic valve function without sig-
nificant (moderate or severe) aortic regurgitation (AR) 
or stenosis, as assessed by echocardiography immedi-
ately after valve deployment and prior to hospital dis-
charge (9). The combined safety outcome at 30 days is 
a composite of all-cause mortality, major stroke, disa-
bling bleeding, severe (Stage 3) acute kidney injury 
(AKI), post-procedure myocardial infarction (MI), 
major vascular complication, and a repeat procedure 
for valve-related dysfunction (9).
The data were collected on a dedicated case report 
form. The pertinent demographics and patient risk 
factors were defined according to the criteria of the 
EuroSCORE registry. In addition, several intraproce-
dural factors were also registered, such as operative 
time, need for mechanical hemodynamic support or 
resuscitation, and blood product usage (for the first 
24 h). The length of intensive care unit (ICU) and hos-
pital stay was recorded. After discharge, patients were 
followed both clinically and by TTE at 3 months and 
annually thereafter.
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Qualitative data are expressed as frequencies and 
percentages, and differences between groups were 
compared with the chi-square test or Fisher’s exact 
test, as appropriate. normally distributed quantitative 
data are expressed as mean ± standard deviations, and 
skewed data are presented as median with its inter-
quartile range (first quartile–third quartile) and ana-
lyzed with the non-parametric Mann–Whitney U-test 
or Student’s t-test, as appropriate. Late survival was 
assessed by Kaplan–Meier analysis, and the log-rank 
test was used to determine the difference in mortality. 
Differences with a two-sided p value <0.05 were con-
sidered as statistically significant. The SPSS version 
20.1 was used for the statistical calculations (IBMCorp, 
Armonk, nY).
RESULTS
The patient demographics and baseline characteristics 
are listed in Table 1. The mean age was 80.2 ± 7.5 years, 
and 53% of the patients were female. The TAo group 
presented an overall higher risk cohort as their mean 
logistic EuroSCORE was 32.6 compared to 25.1 in the 
TA group (p = 0.021). In addition, more TAo patients 
had a decreased left ventricular function (33.3% vs 
14.3%, p  =  0.023). The patient groups did not differ 
with respect to any other baseline characteristics.
The procedural information is depicted in Table 2. 
The average device size was larger in the TAo group 
(p = 0.019). The respective technical success rates for 
the TAo and TA groups were 100% and 95.2%, respec-
tively (p = nS). There was no difference in the proce-
dural time between the groups. The combined rate of 
patients who required cardiopulmonary resuscitation 
(CPR) and/or mechanical hemodynamic support was 
2.8% in the TAo group and 18.8% in the TA group 
(p = 0.023). Three intraprocedural deaths occurred in 
the TA group as opposed to none in the TAo group. 
These deaths were caused by hemodynamic collapse 
in two occasions. The first patient did not recover after 
rapid pacing at the valve implantation and was unre-
sponsive to the CPR. The second had an undersized 
valve deployed that resulted in a severe paravalvular 
leak and progressive hemodynamic deterioration. The 
third intraprocedural death was caused by an aortic 
root rupture of a heavily calcified bicuspid valve on a 
patient who was deemed not to be a candidate for res-
cue open heart surgery.
Two additional patients in the TA group were lost 
within the first day. The first death was caused by an 
apical access site bleeding. The other was due to, 
after a seemingly uncomplicated and successful 
implantation, device migration to ventricular direc-
tion leading to an overhang of the native aortic valve 
leaflets, severe AR, and hemodynamic collapse 8 h 
post-procedure.
The 30-day mortality was 8.6% and 10.9% in the 
TAo and TA group, respectively (p  =  nS) (Table 3). 
There were no major strokes or myocardial infarcts in 
either group, whereas one patient had a Stage 3 kid-
ney failure. Combined safety outcome was met in 
11.1% and 14.1% in the TAo and TA groups, respec-
tively (p = nS)
After the TAVI, the transvalvular gradients decreased 
to 15.6 ± 5.4 mmHg (peak) and 8.8 ± 3.4 mmHg (mean) 
at 3 months with no difference between the groups 
(Table 4). All patients had intravalvular regurgitation 
graded either none/trace or mild. A total of 4.1% of 
patients had paravalvular leakage that was seen as 
more than mild in its severity.
The respective 1-year survival rates for the TAo and 
TA groups were 71.5% and 68.3% (Fig. 1), respectively. 
As the survival curves are virtually overlapping and 
crossing each other twice, no log-rank testing for dif-
ference was performed. The causes of death within 
1 year are listed in Table 5.
TABLE 1
Demographics and baseline characteristics.
Variable Transaortic (TAo) Transapical (TA) p value
Female sex 52.8 (19) 53.1 (34) 0.973
Age (years) 81.7 ± 7.1 79.4 ± 7.7 0.142
Logistic EuroSCORE 32.6 ± 19.5 25.2 ± 12.2 0.021
nYHA-class
 II 2.9 (1) 9.4 (6)  
 III 74.3 (26) 73.4 (47)  
 IV 22.9 (8) 17.2 (11) 0.419
LVEF <40% 33.3 (12) 14.1 (9) 0.023
Coronary artery disease 77.1 (27) 70.3 (45) 0.466
Prior MI 8.3 (3) 19.0 (12) 0.153
CVD 22.2 (8) 25.0 (16) 0.755
Diabetes 22.2 (8) 28.1 (18) 0.518
Chronic renal disease  
Peripheral vascular disease 75.0 (27) 65.1 (41) 0.306
COPD 25.0 (9) 38.1 (24) 0.184
Previous open heart surgery 30.6 (11) 40.1 (26) 0.538
nYHA: new York Heart Association; LVEF: left ventricular ejection fraction; MI: myocardial infarction; CVD: cerebrovascular disease; 
COPD: chronic obstructive pulmonary disease.
Values are given as percentage (number of patients) or mean ± standard deviation.
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DISCUSSIOn
In most institutes, the TA-TAVI has been the primary 
alternative approach for patients unsuitable for the TF. 
The TA approach is, however, associated with more 
acute complications and inferior survival than the TF 
(3–5). The inferior outcome of the TA is mainly caused 
by patient-related factors, as a more morbid patient 
cohort is typically selected for the TA. This might not 
be the only explanation as some studies have found 
the TA access to be an independent predictor of worse 
survival (4, 10).
The novel TAo approach might have some advan-
tages compared to the TA. As a more familiar access to 
the heart surgeons, the TAo offers better bleeding con-
trol strategy, even in the worst-case scenarios of tissue 
disruption. Unlike the apex of the heart, well-proven 
substitutes for the ascending aorta are available (6, 7). 
TABLE 2
Perioperative data.
Variable Transaortic (TAo) Transapical (TA) p value
Device size
 23 27.8 (10) 36.5 (23)  
 26 30.6 (11) 49.2 (31)  
 29 41.7 (15) 14.3 (9) 0.019
Predilation valvuloplasty 94.4 (34) 82.5 (52) 0.092
Procedure time (min) 91 (80–100) 83 (72–95) 0.257
Technical successa 100 (36) 93.8 (60) 0.126
 Unsuccessful vascular access 0 (0) 1.6 (1)  
 Second valve implanted 0 (0) 3.2 (2) 0.280
 Severe paravalvular regurgitation 0 (0) 1.6 (1) 0.419
Periprocedural hemodynamic collapseb 2.8 (1) 18.8 (12) 0.023
 CPR 2.8 (1) 14.1 (9) 0.071
 IABP 0 (0) 4.7 (3) 0.187
 Cardiopulmonary bypass 0 (0) 3.1 (2) 0.284
Procedural mortality 0 (0) 4.7 (3) 0.187
Conversion to open surgery 2.8 (1) 1.6 (1)
Access-related complications 13.9 (5) 14.3 (9) 0.866
Bleeding
 Amount 468 (180–790) 304 (129–547) 0.169
 Major 17.6 (6) 6.3 (4)  
 Life-threatening 5.9 (2) 4.7 (3) 0.131
CPR: cardiopulmonary resuscitation; IABP: intra-aortic balloon pump.
Values are given as percentage (number of patients), or mean ± standard deviation, or median and interquartile range.
a Technical success is defined as successful vascular access, only one valve implanted in proper anatomical location and the absence of 
severe aortic regurgitation or mean aortic valve gradient >20 mmHg.
b Periprocedural hemodynamic collapse is defined as patient requiring CPR, IABP, and/or cardiopulmonary bypass for hemodynamic 
management during the implantation.
TABLE 3
Postoperative complications at 30 days.
Variable Transaortic (TAo) Transapical (TA) p value
Mortality 8.6 (3) 10.9 (7) 0.876
Safety endpoint 11.1 (4) 14.1 (9) 0.674
Myocardial infarction 0 (0) 0 (0)  
Stroke
 Minor 5.6 (2) 0 (0)  
 Major 0 (0) 0 (0) 0.116
Renal failure
 Stage 1 13.3 (4) 7.5 (4)  
 Stage 2 6.7 (2) 5.7 (3)  
 Stage 3 0 (0) 1.9 (1) 0.725
Permanent pacemaker 16.7 (5) 5.4 (3) 0.085
Intensive care unit stay (days) 1 (0–2) 1 (0–2) 0.978
Hospital stay (days) 6 (4–6.8) 7 (6–10) 0.018
Values are given as percentage (number of patients), or mean ± standard deviation, or median and interquartile range.
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The TA approach directly involves myocardium of the 
left ventricle. It is reported that some of the TA patients 
develop a new myocardial hypokinesia or akinesia, 
and in rare cases, false aneurysm formation has been 
observed (11, 12). Furthermore, in the TA approach, 
the delivery system is occupying space in the left ven-
tricle, thereby decreasing the effective ejection frac-
tion. With a retrograde approach, this is obviated, 
probably translating to a hemodynamically more sta-
ble and controlled procedure. Our findings support 
TABLE 4
Echocardiographic data at 3 months (n = 73).
Variable Transaortic (TAo) Transapical (TA) p value
Aortic transvalvular gradient
 Mean (mmHg)  9.8 ± 4.2  8.3 ± 2.9 0.175
 Peak (mmHg) 14.9 ± 6.2 16.0 ± 4.9 0.442
LVEF 53.0 ± 12.6 56.5 ± 7.8 0.203
Intravalvular aortic regurgitation
 0 (none-trace) 96.3 (26) 76.1 (35)  
 1+ (mild) 3.7 (1) 23.9 (11)  
 2+ (moderate) 0 (0) 0 (0)  
 3+ (severe) 0 (0) 0 (0) 0.025
Paravalvular leakage
 0 (none-trace) 51.9 (14) 32.6 (15)  
 1+ (mild) 48.1 (13) 60.9 (28)  
 2+ (moderate) 0 (0) 6.5 (3)  
 3+ (severe) 0 (0) 0 (0) 0.147
LVEF: left ventricular ejection fraction.
Values are given as percentage (number of patients) or mean ± standard deviation.
Number of patients at risk
1 mth 6 mths 12 mths 18mths 24 mths
TA 64 56 42 39 32 25
Tao 36 31 22 16 11 6
Fig. 1. The postoperative survival for the TAo and TA groups.
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these considerations. Although the TAo group had 
more patients with decreased left ventricular function, 
we experienced significantly less difficulties in the 
hemodynamic management of TAo patients. Only one 
patient (2.8%) needed resuscitation or mechanical cir-
culatory support compared to 18.8% in the TA group. 
A total of five patients were lost intraprocedurally or 
within the first 24 h, all in the TA group. However, 
only one of those was directly access-related due to 
apical bleeding that was not timely recognized.
The only major technical contraindications for the 
use of TAo is the inability to have a safe entry into the 
chest or a true porcelain aorta to a degree of not hav-
ing a soft spot for aortic puncture with a minimal 
clearance of 5 cm from the aortic annulus (7). With a 
careful preoperative planning, successful valve 
implantation was achieved in all our TAo procedures, 
and these also included a significant proportion of 
patients with previous coronary artery bypass (CABG) 
surgery (33% of the TAo group) and calcified ascend-
ing aortas. Similar results of successful valve implan-
tation have been published previously, referring to the 
technical feasibility of this method (6–8, 13, 14). Of 
note, in the TAo group larger valve sizes were 
implanted than in the TA counterparts in our study. 
This was not an access-dependent matter but rather 
reflects the later start of the TAo approach, when the 
MDCT was the primary imaging tool for aortic root 
analysis and valve sizing in our institution. Due to our 
positive experience with the TAo approach, we have 
moved to offer the TAo as the first alternative access 
for the SAPIEn valve and reserving the TA access only 
to those who technically can undergo neither the TF 
nor the TAo procedure.
As of now, it is unproven whether the potential ben-
efits of TAo-TAVI could be translated into a better clini-
cal outcome. There is only two small studies published 
where TA and TAo approaches with the SAPIEn valve 
are compared (7, 8). The first US experience reported 
14% mortality in both groups at 30 days (8). In another 
study, mortality was 7.7% in TA group and 11.8% in 
TAo group at 30 days (7). Despite a higher risk patient 
cohort in the TAo group, our results compare favorably 
to these previous studies, with equal outcome in terms 
of mortality and combined safety endpoint in both the 
groups at 30 days. In contrast to Lardizabal et al. (8), we 
did not observe any difference in the postoperative 
bleeding or the ICU stay between the two groups. 
During the 3-month TTE follow-up (FU), there was no 
major intravalvular regurgitation or paravalvular leak-
age observed in either groups in our study. Aortic trans-
valvular gradients were also acceptable in both groups. 
These findings are encouraging considering the long-
term patency of the implanted valves. In summary, our 
procedural success and immediate and short-term 
results using the TAo approach were comparable to the 
TA, supporting our present TAVI strategy.
Long-term survival data where TA and TAo 
approaches are compared are equally scarce, as there is 
only one study dealing with longer than 30-day data. 
Bapat et al. (7) reported that with a limited number of 
patients overall mortality rates were 28.6% for TA 
group at mean FU time of 425 days and 23.5% for TAo 
group at mean FU time of 162 days (nS). In our study, 
the respective 1-year survival rates for the TA and TAo 
groups were 68.3% and 71.5%. no difference in sur-
vival between the groups was observed up to 2 years of 
FU. The significant mid-term mortality reflects the 
extreme-risk nature of patients who are selected for the 
alternative access TAVI. This signals a clear need for 
even more thorough patient screening in order to bet-
ter identify those patients who are capable of achieving 




Transaortic (TAo) Transapical (TA)
Intraprocedural
 Aortic root rupture 1
 Hemodynamic collapse 1
 Severe AR 1
Within 30 days
 Arrhythmia 1
 Bleeding  
  Access-related 1
  Retroperitoneal 1  
 Late valve migration 1
 Pneumonia 1  
 Suffocation 1  
Within 1 year
 Cancer 1  
 Heart failure 2 1
 Pneumonia 1 1
 Renal failure 1
 Sepsis 1  
 Ruptured aortic aneurysm 1
 Unknown 1 3
AR: aortic regurgitation.
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This study has multiple obvious limitations that are 
inherent to a retrospective and a non-randomized sin-
gle-center experience with a limited sample size. First, 
this study cannot be regarded as directly comparative 
due to individual patient selection between the groups. 
Second, the FU time of the patients is still quite limited. 
Third, the original alternative access learning curve 
was with the TA patients. Thus, a negative effect of the 
TA group results by the learning curve cannot be 
excluded. We did not, however, observe a trend toward 
an improved safety profile with increasing operator 
experience for the TA approach. There are studies 
implicating a steep learning curve for the TA with an 
improvement in the outcome first after 150 procedures 
(15). A large-scale, randomized trial is clearly war-
ranted, but the authors are not aware of any plans of 
such being executed in the foreseeable future.
In conclusion, we demonstrate the technical feasi-
bility of the TAo approach. It can be considered as an 
acceptable choice to TA approach. Despite a higher 
risk patient cohort in the TAo group, less intraproce-
dural complications and similar early outcome were 
observed. According to our experience, the TAo 
approach can be instituted as a second choice for 
patients with prohibitive iliac-femoral anatomy for TF 
access. Most importantly, it gives one more access 
option facilitating an individualized tailoring of the 
transcatheter heart valve implantation for this very 
challenging patient population.
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